These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31126975)

  • 41. Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.
    Choi GH; Kim GI; Yoo JE; Na DC; Han DH; Roh YH; Park YN; Choi JS
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1444-52. PubMed ID: 25791790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma.
    Fatourou E; Koskinas J; Karandrea D; Palaiologou M; Syminelaki T; Karanikolas M; Felekouras E; Antoniou E; Manesis EK; Delladetsima J; Tiniakos D
    Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1094-102. PubMed ID: 26011233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
    Yilmaz G; Akyol G; Cakir A; Ilhan M
    Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101.
    Lv X; Li J; Yang B
    Oncol Rep; 2016 Oct; 36(4):2184-92. PubMed ID: 27498785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of activated Cdc42-associated kinase1 (Ack1) predicts tumor recurrence and poor survival in human hepatocellular carcinoma.
    Wang B; Xu T; Liu J; Zang S; Gao L; Huang A
    Pathol Res Pract; 2014 Dec; 210(12):787-92. PubMed ID: 25445114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice.
    Rountree CB; Ding W; He L; Stiles B
    Stem Cells; 2009 Feb; 27(2):290-9. PubMed ID: 19008348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype.
    Krause J; von Felden J; Casar C; Fründt TW; Galaski J; Schmidt C; Jung C; Ittrich H; Weidemann SA; Krech T; Heumann A; Li J; Fischer L; Sauter G; Lohse AW; Wege H; Schulze K
    BMC Cancer; 2020 Nov; 20(1):1130. PubMed ID: 33225916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma.
    Vilchez V; Turcios L; Zaytseva Y; Stewart R; Lee EY; Maynard E; Shah MB; Daily MF; Tzeng CW; Davenport D; Castellanos AL; Krohmer S; Hosein PJ; Evers BM; Gedaly R
    Am J Surg; 2016 Aug; 212(2):238-45. PubMed ID: 27033253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.
    Zeng SS; Yamashita T; Kondo M; Nio K; Hayashi T; Hara Y; Nomura Y; Yoshida M; Hayashi T; Oishi N; Ikeda H; Honda M; Kaneko S
    J Hepatol; 2014 Jan; 60(1):127-34. PubMed ID: 24012616
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
    Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
    J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi.
    Pang YB; Zhong JH; Luo XL; Ou C; Guo Z; Xiang BD; Peng NF; Li LQ
    Tumour Biol; 2016 May; 37(5):5879-84. PubMed ID: 26586401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133- nonstem cell population in hepatocellular carcinoma cell line, HuH-7.
    Karabicici M; Alptekin S; Fırtına Karagonlar Z; Erdal E
    Mol Oncol; 2021 Aug; 15(8):2185-2202. PubMed ID: 33524223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Expressions of phosphorylated-Smad2 and PTEN in hepatocellular carcinomas and adjacent liver tissues].
    Wu SK; Wang BJ; Yang Y; Tian YJ; Bao JJ; Feng XH; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2007 Aug; 15(8):567-71. PubMed ID: 17711623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sorted-Cell Sequencing on HCC Specimens Reveals EPS8L3 as a Key Player in CD24/CD13/EpCAM-Triple Positive, Stemness-Related HCC Cells.
    Tsui YM; Ho DW; Sze KM; Lee JM; Lee E; Zhang Q; Cheung GC; Tang CN; Tang VW; Cheung ET; Lo IL; Chan AC; Cheung TT; Oi-Lin Ng I
    Cell Mol Gastroenterol Hepatol; 2024; 18(3):101358. PubMed ID: 38750898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.
    Tseeleesuren D; Hsiao HH; Kant R; Huang YC; Tu HP; Lai CC; Huang SF; Yen CH
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208536
    [No Abstract]   [Full Text] [Related]  

  • 60. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
    Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
    Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.